Instytut Pomnik Centrum Zdrowia Dziecka
- Address
- lock Available on a paid plan
Gastroenterology and Inflammatory Bowel Disease
At Instytut Pomnik Centrum Zdrowia Dziecka, a major focus is on digestive system diseases and immune system disorders, especially pediatric Crohn's disease and ulcerative colitis. The trials are designed to assess new and existing therapies that may help control inflammation, improve remission rates, and support safer long-term care for children and adolescents.
- Moderately to severely active Crohn's disease and ulcerative colitis
- Inflammatory bowel diseases with a focus on treatment effectiveness and safety
- Complex perianal fistulas associated with Crohn's disease
Research in this area includes evaluating therapies for symptom control, remission, and broader disease management in young patients.
Pediatric Neurology and Demyelinating Disease
The site also contributes to studies in nervous system diseases, with attention to relapsing-remitting multiple sclerosis in children and adolescents. These trials aim to better understand treatment response, monitor safety, and support more effective management of chronic neurological illness.
- Relapsing-remitting multiple sclerosis in pediatric patients
- Evaluation of treatment effectiveness and safety in neurologic disorders
- Studies of how therapies behave in children and adolescents
This research reflects the department’s strength in pediatric neurology and its interest in improving care for complex long-term conditions.
Pediatric Metabolic and Endocrine Research
Clinical trials at the Warsaw site include nutritional and metabolic diseases, particularly type 1 diabetes mellitus. The research is centered on preserving natural insulin production and evaluating whether new approaches can improve disease control soon after diagnosis.
- Type 1 diabetes mellitus in newly diagnosed children and adolescents
- Testing strategies to preserve endogenous insulin secretion
- Assessing treatment benefit alongside standard diabetes care
These studies aim to support better long-term outcomes for young people living with diabetes.
Rare Pediatric Liver and Congenital Disorders
Another important theme is congenital, hereditary, and neonatal diseases, including biliary atresia. The trials in this field are focused on supporting liver health and examining whether new treatments can help improve survival and long-term outcomes in children with rare conditions.
- Biliary atresia and related pediatric liver disease
- Evaluation of therapies aimed at improving native liver survival
- Research on treatment durability and ongoing safety
This line of research addresses serious early-life disorders where effective treatment options are especially important.
Cardiopulmonary and Imaging Studies
The clinical portfolio also spans respiratory tract diseases and advanced diagnostic techniques, including work in pulmonary arterial hypertension and pediatric contrast-enhanced magnetic resonance imaging. These studies are intended to improve disease monitoring, test supportive therapies, and refine diagnostic performance in children.
- Pulmonary arterial hypertension in pediatric patients
- Research on treatment added to standard care to slow disease progression
- Imaging studies assessing safety and body handling of contrast agents in children
By combining therapeutic and diagnostic research, the Institute of the Memorial Health Institute for Children supports more precise pediatric care across several complex conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 20 therapeutic areas and 15 of 129 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 127 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 34 by active trials.
lock +33 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Instytut Pomnik Centrum Zdrowia Dziecka
lock Showing 1 of 102 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21196) A multicenter, prospective, open-label study to evaluate the pharmacokinetics and safety of gadoquatrane in pediatric participants (from birth to <18 years) undergoing contrast-enhanced magnetic resonance imaging (CE-MRI) | Bayer AG | Phase III | Not Yet Recruiting | Oct 2023 | Nov 2024 |
IMP list
lock Showing 1 of 129 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vedolizumab | 7 | Unknown | 2021-12-17 | 2025-10-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.